Division of Gastroenterology and Hepatology, Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, 7340 MBRB Building, 111 Mason Farm Road, Chapel Hill, NC, 27599, USA.
Bacteriotherapy Clinic, Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, 6 Weizmann St., Tel Aviv, Israel.
Dig Dis Sci. 2018 Jul;63(7):1890-1899. doi: 10.1007/s10620-018-5086-4. Epub 2018 May 17.
Irritable bowel syndrome (IBS) has been associated with changes in the intestinal microbiota. Only a few studies have explored differences in the mucosa-associated microbiota between IBS patients and healthy controls (HC).
To characterize and compare the microbiota in mucosal and fecal samples from carefully selected patients with IBS-D and HC.
The cohort was composed of 23 diarrhea-predominant IBS (IBS-D) patients and 24 HC. Fresh stool samples were collected from participants prior to the collection of colonic mucosal samples from an unprepped bowel. After DNA extraction, 16S rRNA genes were sequenced by 454 pyrosequencing and analyzed using the QIIME pipeline.
The fecal microbiota (luminal niche) of IBS-D patients was found to have reduced enteric richness compared to HC (P < 0.05), whereas no differences were observed between the two groups within the mucosal microbiota. Within the luminal niche, the relative proportions of Faecalibacterium genus were found to be lower in IBS-D than in HC and the Dorea genus was higher in IBS-D. None of the taxa proportions were significantly different in IBS-D patients versus HC using an FDR of ≤ 0.1 when analyzing samples that appeared in > 25% samples of either niche.
Fecal and mucosal microbiota of IBS-D patients and HC are very similar and are not sufficient to explain the reported altered physiology and symptomatology of IBS-D. Future studies should investigate intestinal microbiome-dependent functional activity in addition to the fecal and mucosal-associated microbial composition.
肠易激综合征（IBS）与肠道微生物群的变化有关。只有少数研究探讨了 IBS 患者与健康对照者（HC）之间黏膜相关微生物群的差异。
描述和比较精心挑选的 IBS-D 患者和 HC 的黏膜和粪便样本中的微生物群。
该队列由 23 例腹泻为主的 IBS（IBS-D）患者和 24 例 HC 组成。在未准备肠道的情况下，从参与者中采集新鲜粪便样本，然后采集结肠黏膜样本。提取 DNA 后，通过 454 焦磷酸测序对 16S rRNA 基因进行测序，并使用 QIIME 管道进行分析。
与 HC 相比，IBS-D 患者的粪便微生物群（腔隙）的肠道丰富度较低（P<0.05），而两组之间在黏膜微生物群中没有差异。在腔隙内，IBS-D 患者的 Faecalibacterium 属的相对比例低于 HC，而 Dorea 属的比例高于 IBS-D。当分析出现在两种生态位中任一生态位的样本超过 25%的样本时，使用 FDR≤0.1 分析，IBS-D 患者与 HC 相比，没有任何分类群的比例存在显著差异。
IBS-D 患者和 HC 的粪便和黏膜微生物群非常相似，不足以解释报道的 IBS-D 改变的生理学和症状。未来的研究应在粪便和黏膜相关微生物组成之外，研究肠道微生物组依赖的功能活性。
